Phase i trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 1, 2012, Pages 184-190

  Adkison, Jarrod B ^a   McHaffie, Derek R ^a   Bentzen, Søren M ^a   Patel, Rakesh R ^a   Khuntia, Deepak ^a   Petereit, Daniel G ^b   Hong, Theodore S ^a   Tomé, Wolfgang ^a   Ritter, Mark A ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b RAPID CITY REGIONAL HOSPITAL   (United States)

Author keywords

Bowel displacement board; Hypofractionated radiation therapy; Image guided prostate intensity modulated radiation therapy; Pelvic lymph node dose escalation; Rectal balloon

Indexed keywords

ADVERSE EVENTS; ANDROGEN DEPRIVATION; BIOCHEMICAL CONTROL; BOWEL DISPLACEMENT BOARD; CLINICAL FAILURE; COMMON TERMINOLOGY CRITERIA; DESCRIPTORS; DOSE ESCALATION; DOSE-VOLUME; GASTROINTESTINAL TOXICITIES; HIGH-RISK PATIENTS; IMAGE-GUIDED; INTENSITY-MODULATED RADIATION THERAPY; PELVIC LYMPH NODES; PELVIC RADIATION; PHASE I; POTENTIAL BENEFITS; PROSTATE CANCERS; PROSTATE RADIOTHERAPY; RADIATION THERAPY ONCOLOGY GROUPS;

DISEASES; RADIOTHERAPY; TOXICITY;

PHYSICAL THERAPY;

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CAUTERIZATION; CLINICAL TRIAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION SAFETY; RECTUM HEMORRHAGE; TREATMENT DURATION; TREATMENT FAILURE; URINE RETENTION; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DOSE FRACTIONATION; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PELVIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; UROGENITAL SYSTEM;

EID: 83955161794     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.09.018     Document Type: Article

References (35)

1. M. Roach 3rd, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911
2. C.A. Lawton, M. DeSilvio, and M. Roach 3rd An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655
3. S.O. Asbell, J.M. Krall, and M.V. Pilepich Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77-06 Int J Radiat Oncol Biol Phys 15 1988 1307 1316
4. P. Pommier, S. Chabaud, and J.L. Lagrange Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 5373
5. C.R. King, and D.S. Kapp Radiotherapy after prostatectomy: Is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 71 2008 346 350
6. C.R. King, and M.T. Spiotto Improved outcomes with higher doses for salvage radiotherapy after prostatectomy Int J Radiat Oncol Biol Phys 71 2008 23 27
7. T.G. Shanahan, M.P. Mehta, and K.L. Bertelrud Minimization of small bowel volume within treatment fields utilizing customized "belly boards" Int J Radiat Oncol Biol Phys 19 1990 469 476
8. M. Ritter, J. Forman, and P. Kupelian Hypofractionation for prostate cancer Cancer J 15 2009 1 6
9. A.W. Partin, L.A. Mangold, and D.M. Lamm Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium Urology 58 2001 843 848
10. T.S. Hong, W.A. Tome, and H. Jaradat Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy Acta Oncol 45 2006 717 727
11. C.A. Lawton, J. Michalski, and I. El-Naqa RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer Int J Radiat Oncol Biol Phys 74 2009 383 387
12. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
13. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
14. M. Roach 3rd, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
15. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
16. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 106
17. I. Cagiannos, P. Karakiewicz, and J.A. Eastham A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer J Urol 170 2003 1798 1803
18. D.L. Bluestein, D.G. Bostwick, and E.J. Bergstralh Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer J Urol 151 1994 1315 1320
19. A. Briganti, P.I. Karakiewicz, and F.K. Chun Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection Eur Urol 51 2007 1573 1581
20. A. Briganti, F.K. Chun, and A. Salonia Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy Eur Urol 49 2006 1019 1026 discussion 1026-1017
21. S. Conrad, M. Graefen, and U. Pichlmeier Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma J Urol 167 2002 521 525
22. P. Bader, F.C. Burkhard, and R. Markwalder Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168 2002 514 518 discussion 518
23. A. Heidenreich, Z. Varga, and R. Von Knobloch Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis J Urol 167 2002 1681 1686
24. A. Briganti, F.K. Chun, and A. Salonia Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy Urology 69 2007 147 151
25. M. Golimbu, P. Morales, and S. Al-Askari Extended pelvic lymphadenectomy for prostatic cancer J Urol 121 1979 617 620
26. F.C. Burkhard, P. Bader, and E. Schneider Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection Eur Urol 42 2002 84 90 discussion 90-82
27. T. Clark, D.J. Parekh, and M.S. Cookson Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer J Urol 169 2003 145 147 discussion 147-148
28. P.L. Nguyen, M.H. Chen, and K.E. Hoffman Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era Int J Radiat Oncol Biol Phys 74 2009 104 109
29. M.G. Harisinghani, J. Barentsz, and P.F. Hahn Noninvasive detection of clinically occult lymph-node metastases in prostate cancer N Engl J Med 348 2003 2491 2499
30. R.A. Heesakkers, G.J. Jager, and A.M. Hovels Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging Radiology 251 2009 408 414
31. J. Bernier, C. Domenge, and M. Ozsahin Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer N Engl J Med 350 2004 1945 1952
32. R. McCammon, K.E. Rusthoven, and B. Kavanagh Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer Int J Radiat Oncol Biol Phys 75 2009 413 420
33. Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys xxx;76:S101-S107.
34. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
35. P.A. Kupelian, T.R. Willoughby, and C.A. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430